No Data
Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Cuts Target Price to $8
Express News | Karyopharm Therapeutics Inc : Piper Sandler Cuts Target Price to $8 From $12
Karyopharm Strengthens Liquidity With New Equity Financing
Express News | Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $15
Baird Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Cuts Target Price to $15
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $8
Xue(SG) : Cut at 5.91